iBio, Inc. (IBIO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

iBio, Inc. (IBIO) is down 9.8% since the beginning of the year. At $2 per share, IBIO is trading 54.5% below its 52-week high of $4. Investors who bought $1,000 worth of IBIO shares 5 years ago would now be looking at an investment worth $2.

iBio, Inc. (IBIO) has returned -9.84% so far this year and 125.68% over the past 12 months. Over the last ten years, IBIO has returned -52.79% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Aug 19, 2008, IBIO's average daily return is +0.24%, while the average monthly return is +5.78%. At this rate, an investment would double in approximately 1.0 years.

Historically, 41% of months were positive and 59% were negative. The best month was Feb 2020 with a return of +775.0%, while the worst month was Dec 2008 at -73.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.

On a daily basis, IBIO closed higher 40% of trading days. The best single day was Mar 27, 2024 with a return of +192.2%, while the worst single day was Dec 7, 2022 at -57.9%.

iBio, Inc. has an annualized alpha of 77.83%, beta of 0.28, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since August 19, 2008.

• This stock participated in 155.88% of S&P 500 Index downside but only -26.68% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.28 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

IBIO ranks 77 for risk / return — better than 77% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the iBio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the iBio, Inc. was 100.00%, occurring on Aug 12, 2025. The portfolio has not yet recovered.

The current iBio, Inc. drawdown is 99.99%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of iBio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how iBio, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.